Results 21 to 30 of about 3,554 (229)

Cost-Utility of Acromegaly Pharmacological Treatments in a French Context

Frontiers in Endocrinology, 2021
ObjectiveEfficacy of pharmacological treatments for acromegaly has been assessed in many clinical or real-world studies but no study was interested in economics evaluation of these treatments in France.
Thierry Brue, Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marié, Laurène Juban, Lara Salvi, Robin Henocque, Gérald Raverot   +10 more
doaj   +1 more source

Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis. [PDF]

Endocr Connect
Giampietro A, Chiloiro S, Urbani C, Pivonello R, Carlsson MO, Dassie F, Prencipe N, Ragonese M, Gomez R, Granato S, Cannavò S, Grottoli S, Maffei P, Colao A, Bogazzi F, Bianchi A.   +15 more
europepmc   +3 more sources

Pegvisomant [PDF]

pharma-kritik, 2008
Ein gentechnisch hergestelltes Derivat des Wachstumshormons, das sich zur Behandlung der Akromegalie eignet. wenn diese nicht zufriedenstellend chirurgisch, radiotherapeutisch oder  mit anderen Medikamenten behandelt werden kann.
  +4 more sources

Pegvisomant: uso clínico en pacientes con acromegalia

Revista Colombiana de Endocrinología, Diabetes y Metabolismo, 2022
Contexto: el manejo de los pacientes con acromegalia actualmente incluye cirugía, radioterapia y terapia farmacológica. Aunque la cirugía es el tratamiento de primera línea, un gran porcentaje de pacientes van a requerir manejo adicional con ...
Alejandro Román-González, Huber Padilla-Zambrano, Carlos Alfonso Builes-Barrera, Henry Tovar   +3 more
doaj   +1 more source

Experiense of treatment with a growth hormone receptor antagonist in patients with hereditary form of acromegaly: clinical cases

Ожирение и метаболизм, 2022
Acromegaly is a severe neuroendocrine disease caused by chronic excessive production of somatotropic hormone (STH), characterized by specific changes in appearance, metabolic disorders.
L. K. Dzeranova, A. V. Dorovskikh, E. A. Pigarova, E. G. Przhiyalkovskaya, A. S. Shutova, M. I. Yevloyeva, A. Yu. Grigoriev, V. N. Azizyan, O. V. Ivashchenko   +8 more
doaj   +1 more source

A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. [PDF]

, 2013
Fibroblast growth factor-1 (FGF1) and FGF2 play a critical role in angiogenesis, a formation of new blood vessels from existing blood vessels. Integrins are critically involved in FGF signaling through crosstalk. We previously reported that FGF1 directly
Fujita, Masaaki, Hamada, Yoshinosuke, Kaneda, Teruya, Kawaguchi, Naomasa, Matsuura, Nariaki, Mori, Seiji, Nishikawa, Kyoko, Saegusa, Jun, Takada, Yoko K, Takada, Yoshikazu, Tran, Vu, Zhao, Min   +11 more
core   +6 more sources

New opportunities for secondary drug therapy of acromegaly

Медицинский совет, 2020
Introduction. Acromegaly is a severe multi-organ disease that negatively affects the quality and life expectancy of patients. The continuing complexity of acromegaly curation is due to the multiplicity of pathomorphological variants growth hormone ...
V. S. Pronin, E. V. Pronin
doaj   +1 more source

Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series

Journal of Medical Case Reports, 2012
Introduction Pegvisomant-related lipohypertrophy may revert when changing the site of injection, but the lipohypertrophy may recur at the new site of injection.
Rochira Vincenzo, Zirilli Lucia, Diazzi Chiara, Romano Stefania, Carani Cesare   +4 more
doaj   +1 more source

The position of combined medical treatment in acromegaly

Archives of Endocrinology and Metabolism, 2020
Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies.
Eva C. Coopmans, Sebastiaan W. F. van Meyel, Aart J van der Lely, Sebastian J. C. M. M. Neggers   +3 more
doaj   +1 more source

Uso de lanreotida en combinación con cabergolina o pegvisomant en la práctica clínica en pacientes con acromegalia: el estudio ACROCOMB [PDF]

, 2016
[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy
Bernabéu, Ignacio, Blanco, Concepción, Casany, Rosa, Cordido, Fernando, Cuatrecasas, Guillem, Fajardo, Carmen, Gálvez, María Ángeles, Lucas, Tomás, Maraver, Silvia, Marazuela, Mónica, Martín, Tomás, Paja, Miguel, Picó, Antonio, Puig-Domingo, Manuel, Resmini, Eugenia, Romero, Enrique, Soto, Alfonso, Venegas, Eva, Vílchez, Ricardo   +18 more
core   +2 more sources